Impact of Solitary Involved Lymph Node on Outcome in Localized Cancer of the Esophagus and Esophagogastric Junction by O’Riordan, James M. et al.
Impact of Solitary Involved Lymph Node on Outcome
in Localized Cancer of the Esophagus
and Esophagogastric Junction
James M. O’Riordan & Suzanne Rowley &
James O. Murphy & Narayasami Ravi &
Patrick J. Byrne & John V. Reynolds
Published online: 30 January 2007
# 2007 The Society for Surgery of the Alimentary Tract
Abstract Node-positive esophageal cancer is associated with a dismal prognosis. The impact of a solitary involved node,
however, is unclear, and this study examined the implications of a solitary node compared with greater nodal involvement
and node-negative disease. The clinical and pathologic details of 604 patients were entered prospectively into a database
from1993 and 2005. Four pathologic groups were analyzed: node-negative, one lymph node positive, two or three lymph
nodes positive, and greater than three lymph nodes positive. Three hundred and fifteen patients (52%) were node-positive
and 289 were node-negative. The median survival was 26 months in the node-negative group. Patients (n=84) who had one
node positive had a median survival of 16 months (p=0.03 vs node-negative). Eighty-four patients who had two or three
nodes positive had a median survival of 11 months compared with a median survival of 8 months in the 146 patients who
had greater than three nodes positive (p=0.01). The survival of patients with one node positive [number of nodes (N)=1]
was also significantly greater than the survival of patients with 2–3 nodes positive (N=2–3) (p=0.049) and greater than
three nodes positive (p<0001). The presence of a solitary involved lymph node has a negative impact on survival compared
with node-negative disease, but it is associated with significantly improved overall survival compared with all other nodal
groups.
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Introduction
Carcinoma of the esophagus carries a dismal prognosis, and
for patients presenting with localized resectable disease,
multivariate analysis has established that the presence or
absence of involved lymph nodes confers the greatest
prognostic significance.
1 In surgical management, the
extent and type of lymphadenectomy undertaken varies
from no formal lymphadenectomy to two and three field
dissection.
2–5 The presence and extent of lymph node
involvement is important as selective approaches may be
considered depending on the nodal stage at presentation. In
early tumors, for instance, the sentinel node concept
initially developed in melanoma and breast cancer was
explored to help identify patients who may not require
lymph node dissection.
6–8 The advent of minimally
invasive esophagectomy may also highlight the need to
subselect patients for lymphadenectomy.
9
In the observations of the senior author (JVR), patients
with solitary involved lymph nodes may achieve good
outcomes, and this hypothesis was evaluated in this
analysis of a large prospective database. We report herein
that the cohort with a solitary node involved had cancer
outcomes closer to node-negative disease than other node-
positive subgroups, and suggest that this represents a
distinct prognostic subgroup.
Patients and Methods
The study population consisted of all patients with tumors
of the esophagus and esophagogastric junction who
underwent surgical resection, either alone or preceded by
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Patients receiving multimodal therapy received cisplatin,
5-fluorouracil, and external beam radiotherapy (40–44 Gy,
2–2.67 Gy/fraction) as previously described.
10 Data
concerning the clinical and pathologic parameters for all
patients was obtained from a detailed prospective database
maintained by a full-time data manager. Pathologic param-
eters analyzed included the location of the tumor, tumor
morphology, i.e., adenocarcinoma or squamous cell carci-
noma, histological differentiation (grade), TNM staging,
number and site of involved lymph nodes, and R
classification after surgical resection. Staging of tumors
was performed according to the American Joint Committee
on Cancer TNM system.
11
A subtotal esophagectomy was performed with a sutured
anastomosis either in the right thorax (two-stage) or neck
(three-stage). All cases underwent a formal abdominal
lymphadenectomy and mediastinal lymph node dissection
up to and including the subcarinal nodes. Thoracic nodes
were submitted separately to abdominal nodes.
Statistical Analysis
Data are presented as frequencies, means, and percentages.
ANOVA was used for comparison of the four demographic
groups. Survival probability was estimated using the
Kaplan–Meier method. Survival was calculated from the
date of clinical diagnosis to date of death or date last seen.
In the multivariate analysis, independent prognostic factors
for survival were determined by using a Cox regression
hazard model. Two analyses were performed, one for all
patients and the other exclusive to node-positive patients.
All statistical analyses were performed using Stata software
(version 9.1 for Windows, Statcorp, TX). A p value <0.05
was considered statistically significant.
12
Results
Patients/histology
Six hundred and four patients underwent surgery for
localized malignancy of the esophagus or esophagogastric
junction. The mean age was 62±10.4 (median=64, range
56 to 70). Four hundred and twelve (68%) patients were
men. The mean number of lymph nodes examined per
specimen was 12±6 (median=10, range=6 to 55). Two
hundred and eighty-nine patients (48%) had node-negative
disease [number of nodes (N)=0], 84 (14%) had one node
positive (N=1), 84 had two or three nodes positive, and 147
(24%) had greater than three nodes positive (N>3). In
patients with one involved node, in all cases the node was
adjacent to the tumor, mediastinal for esophageal tumors,
and periesophageal or along the left gastric artery for
junctional tumors (Tables 1 and 2).
Two hundred and two patients (33%) had multimodal
therapy and 402 patients (67%) had surgery alone. Of the
multimodal cohort, 129 (64%) were ypN0 on histopatho-
logic assessment, 28 (14%) had one node positive, 24
(12%) had two to three positive nodes, and 21 (10%) had
greater than three positive nodes. The attainment of an R0
resection was significantly greater in patients with none or
one node involved compared with both other groups (p<
0.05). The majority of patients in all groups had pT3
tumors, 48% in the pN0 group compared with 71, 64, and
82% in the N=1, N=2–3, and N>3 groups, respectively (p<
0.05). One hundred and forty (62%) of the squamous cell
carcinoma cohort were node-negative (N=0) compared with
140 (39%) of cases with adenocarcinoma (39%) (p<0.05).
Table 1 Demographics of Nodal Subgroups
Histologic Data N=0
(n=289)
N=1
(n=84)
N=2–3
(n=84)
N>3
(n=147)
Tumor site (%)
Lower esophagus 138 (47) 39 (46) 37 (44) 57 (39)
EG junction 80 (28) 35 (42) 33 (39) 75 (51)
Middle esophagus 55 (19) 10 (12) 12 (14) 11 (7)
Upper esophagus 16 (6) 0 2 (3) 4 (3)
Morphology (%)
Adenocarcinoma 140 (48) 51 (61) 57 (68) 113 (77)
Squamous cell
carcinoma
140 (48) 29 (35) 25 (30) 32 (22)
Others 9 (4) 4 (5) 2 (1) 2 (1)
Treatment (%)
Multimodal therapy 129 (44) 28 (33) 24 (29) 21 (14)
Surgery alone 161 (56) 56 (76) 60 (71) 125 (86)
Residual tumor (%)
R0: no residual tumor 250 (86) 71 (85) 64 (76) 108 (73)
R1: residual tumor
found
39 (13) 13 (15) 19 (23) 39 (27)
Rx: unknown 1 (1) – 1 (1) –
Pathological stage (%)
Stage 0 53 (18) –––
Stage I 59 (20) 1 (1) ––
Stage II 170 (59) 21 (25) 25 (30) 16 (11)
Stage III 5 (2) 58 (29) 53 (63) 110 (76)
Stage IV 1 (1) 4 (5) 6 (7) 20 (13)
pT stage (%)
Tx 3 (1) 0 2 (3) 1 (0.5)
Tis 12 (4) 0 0 0
T0 40 (14) 1 (1) 2 (3) 2 (1)
T1 56 (19) 5 (6) 4 (5) 3 (2)
T2 35 (12) 16 (19) 18 (21) 12 (8)
T3 138 (48) 60 (71) 54 (64) 120 (82)
T4 6 (2) 2 (3) 4 (5) 8 (5)
EG = esophagogastric
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The median survival for all patients was 20 months at a
median follow-up of 19 months (3–167). Patients who were
node-negative (N=0) had a median survival of 26 months
(Table 3), compared with 16 months when one node was
positive (p=0.03). Patients who had two to three nodes
positive had a median survival of 11 months, and 8 months in
patients who had greater than three nodes positive (p=0.01;
N=2–3v sN>3). The survival of patients with one node
positive (N=1) was significantly greater than the survival of
patients with 2–3 nodes positive (p=0.04) and the cohort with
greater than three involved nodes (p<0.0001).
The 1-, 3-, and 5-year survival of the pN0 group was 78,
51, and 44%, respectively (Fig. 1). Where one node was
involved, survival was 67, 41, and 35%, respectively.
Where two to three nodes were involved, the 1-, 3-, and
5-year survival was 57, 25, and 13%, respectively, and
where greater than three nodes were involved, this was 40,
14, and 8%, respectively.
Univariate analysis (Table 3) revealed nodal status, pT
stage, pathologic stage, and R status as predictors of
survival. Multivariate analysis revealed nodal status alone
to significantly (p<0.0001) impact on survival. By this
analysis the hazards ratio increased from 1.08 for one
involved node to 1.42 for two to three involved nodes, and
1.84 for greater than three nodes.
Excluding node-negative patients, univariate analysis
(Table 4) revealed pT stage, pathologic stage, R status,
and number of nodes as predictive of survival. By
multivariate analysis (Table 5), pathologic stage (p=0.010)
and number of nodes were significant determinants of
survival. Compared with the cohort with one involved
node, the hazard ratio for two to three nodes was 1.56 (p=
0.049) and 2.06 (p=0.007) for greater than three nodes.
Discussion
Cancers of the esophagus and esophagogastric junction are
aggressive tumors, which are typically diagnosed at an
advanced stage of disease progression.
13 This large retro-
spective review of a tertiary center’s experiences over
12 years highlights the importance of lymph node involve-
Table 2 Histology of Nodal Subgroups
Histologic Data N=0 N=1 N=2–3 N>3
Adeno SCC Adeno SCC Adeno SCC Adeno SCC
n=140 n=140 n=51 n=29 n=57 n=25 n=113 n=32
No % No % No % No % No % No % No % No %
Tumor site
Lower Esophagus 64 (46) 66 (47) 19 (52) 15 (52) 23 (40) 13 (52) 39 (35) 17 (53)
EG Junction 73 (52) 6 (4) 31 (10) 3 (10) 33 (58) 0 0 74 (65) 1 (3)
Middle Esophagus 3 (2) 52 (37) 1 (28) 8 (28) 1 (2) 10 (40) 0 0 10 (31)
Upper Esophagus 0 0 16 (11) 0 (10) 3 (10) 0 0 2 (8) 0 0 4 (13)
Treatment
Multimodal 80 (57) 46 (34) 23 (45) 5 (17) 20 (35) 4 (16) 19 (13) 3 (10)
Surgery alone 60 (43) 93 (66) 28 (55) 24 (83) 37 (65) 21 (84) 94 (87) 28 (90)
Path stage
Stage 0 29 (21) 18 (13) 0 0 0 0 0 0 0 0 0 0 0 0
Stage 1 42 (30) 15 (10) 1 (2) 0 0 0 0 0 0 0 0 0 0
Stage 2 66 (47) 102 (73) 15 (29) 4 (14) 19 (33) 5 (20) 15 (13) 1 (3)
Stage 3 2 (1) 4 (3) 32 (63) 24 (83) 35 (61) 17 (68) 82 (73) 27 (84)
Stage 4 0 0 1 (1) 3 (6) 1 (3) 3 (6) 3 (12) 16 (914) 3 (10)
Unknown 1 (1) 0 0 0 0 0 0 0 0 0 0 0 0 1 (3)
pT stage
Tx 2 (1) 1 (1) 0 0 0 0 0 0 2 (8) 0 0 1 (3)
T i s 9( 6 ) 0 0 00 00 2( 4 ) 00 00 00
T0 19 (14) 17 (12) 1 (2) 0 0 3 (5) 0 0 2 (2) 0 0
T1 39 (29) 15 (11) 4 (8) 0 0 14 (24) 0 0 3 (3) 0 0
T2 16 (11) 19 (14) 12 (23) 3 (10) 36 (63) 4 (16) 11 (10) 1 (3)
T3 53 (38) 84 (60) 33 (65) 26 (90) 2 (4) 17 (68) 91 (80) 28 (88)
T4 2 (1) 4 (2) 1 (2) 0 0 0 0 2 (8) 6 (5) 2 (6)
Adeno = adenocarcinoma, SCC = small cell carcinoma, EG = esophagogastric
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the presence of a solitary node, although a significantly
negative factor compared with pN0 disease, is associated
with significantly improved median and 1-, 3-, and 5-year
survival compared with cohorts of patients with greater
nodal involvement. The 5-year survival, for instance, was
35% compared with 13 and 8%, respectively, for cohorts
with two to three positive nodes and greater than three
positive nodes.
There is no uniform consensus on the number of lymph
nodes that must be sampled. In a study by Ito et al.,
3 the
median number of lymph nodes examined per specimen
was 6 (range 0 to 35) and only 20% of patients had at least
15 lymph nodes examined. In this study, the median
number of lymph nodes examined per specimen was 12
(range 6 to 55), and 24% of the patients had at least 15
lymph nodes examined. These results appear consistent
with practice in the United States where an analysis of the
National Cancer Database indicated that only 18% of
patients undergoing surgery for gastric cancer have more
than 15 lymph nodes analyzed.
14 In this Unit, lymph node
clearance involves a D2 dissection of abdominal nodes, and
wide mediastinal clearance to the carina and paratracheal
node dissection if they appear involved. No cervical
dissection is performed, consistent with recommendations
from another group.
15 It is acknowledged that variation in
lymph node yield may mask stage migration, particularly in
a retrospective analysis, but the standardization of lympha-
denectomy is likely to minimize the impact of this potential
bias.
The association between extent of nodal involvement
and outcome is well described.
16–18 N os t u d yt oo u r
Table 3 Univariate and Multivariate Analysis: All Patients
Variables No. of
Patients
Median Survival
(moths)
p Value
a
(Univariate)
HR 95% CI
a p value
b
(Multivariate)
HR 95% CI
Treatment
Surgery only 401 13 0.077 1 –– –
Multimodal 203 19 0.84 0.69–1.02
Tumor site
Upper esophagus 25 16 0.371 1 –– –
Middle esophagus 87 14 0.946 0.98 0.58–1.66
Lower esophagus 268 14 0.658 1.16 0.69–1.81
EG junction 224 14 0.624 1.13 0.69–1.84
Depth of invasion
T0 57 55 <0.001 1 0.652 1
T1 68 26 0.537 1.16 0.73–1.83 0.472 0.71 0.21–2.3
T2 81 26 0.419 1.20 0.77–1.85 0.573 1.11 0.31–3.94
T3 373 11 <0.001 2.28 1.60–3.26 0.871 1.40 0.79–2.41
T4 19 7 <0.001 4.34 2.46–7.68 0.649 2.59 1.42–4.08
No. of nodes
0 289 26 <0.001 1 <0.001 1 0.63–1.87
1 84 16 0.038 1.36 1.02–1.82 0.774 1.08 0.83–2.43
2–3 84 11 <0.001 1.91 1.45–2.52 0.202 1.42 1.07–3.18
>3 147 8 <0.001 2.61 2.08–3.29 0.027 1.84
Histology
Squamous 361 14 0.916 1
Adenocarcinoma 224 13 0.596 1.05 0.87–1.28 –– –
Other 19 26 0.483 0.80 0.44–1.48
Stage
0 53 55 <0.001 1 0.118 1
I 63 55 0.747 0.92 0.56–1.51 0.576 0.68 0.18–2.59
II 230 20 0.037 1.49 1.02–2.17 0.508 1.55 0.42–4.69
III 225 10 <0.001 2.71 1.86–3.95 0.527 1.68 0.34–5.58
IV 31 6 <0.001 6.16 3.72–10.2 0.182 3.14 1.14–7.76
Residual tumor
R0 492 17 <0.001 1 0.052 1
R1 110 8 1.70 1.37–2.12 1.25 0.99–1.58
aχ
2
bCox regression
HR = hazard ratio, CI = 95% confidence intervals, EG = esophagogastric
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number of nodes positive.
Variables No. of
Patients
Median Survival
(moths)
p value
a
(Univariate)
HR 95% CI
Treatment
Surgery only 241 11 0.234 1 0.63–1.11
Multimodal 74 11 0.84
Tumor site
Upper esophagus 9 18 0.650 1
Middle esophagus 32 10 0.556 1.31 0.54–3.18
Lower esophagus 130 10 0.183 1.75 0.77–3.98
OG junction 144 12 0.350 1.48 0.65–3.36
Depth of invasion
T0 5 11 0.001 1
T1 12 8 0.917 1.06 0.33–3.41
T2 46 24 0.176 1.12 0.43–1.78
T3 235 11 0.757 1.43 0.74–2.14
T4 14 5 0.157 2.23 0.74–6.78
Histology
Squamous 86 11 0.638 1
Adenocarcinoma 221 11 0.638 1.07 0.81–1.40
Other 8 3 0.848 1.07 0.49–2.35
Stage
1–II 63 19 <0.001 1
III–IV 251 10 2.01 1.43–2.83
Residual tumor
R0 259 12 0.035 1
R1 61 9 1.33 1.02–1.73
No. of nodes
1 84 17 <0.001 1
2–3 84 13 0.021 1.67 1.06–2.29
>3 147 9 <0.001 2.53 1.50–3.62
Table 4 Univariate Analysis:
Node-positive Alone
aχ
2
HR = hazard ratio, CI = 95%
confidence intervals
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positive node on outcome in esophageal cancer. The
observation, however, of the unique prognostic significance
of a solitary involved node was recently reported.
19 In a
study of 187 patients with esophageal adenocarcinoma
treated with neoadjuvant chemoradiotherapy, Gu et al.
19 at
the MD Anderson observed from their analysis that patients
with a solitary involved node had better overall and relapse-
free survival compared with other nodal groups. Moreover,
the 5-year survival outcomes and 2-year relapse-free
survival was not significantly different from the node-
negative cohort. Although in our series survival figures
were better for node-negative patients than patients with a
solitary involved node, the overall pattern of outcome data
in our series is consistent with the report from the Anderson
group, with prognosis in this cohort closer to node-negative
than other node-positive subgroups.
The clinical implication of this finding is not clear at this
time, but it should, at minimum, encourage a more
optimistic view of patients who have a solitary lymph node
identified after adequate lymphadenectomy, as approxi-
mately 35% of patients with this pathologic stage may be
cured. In the future, it is possible that advances in
endoscopic US staging, fluorodeoxyglucose PET, and
sentinel node assessment may improve pre- and intra-
operative assessment of nodal involvement, defining node-
negative, solitary involved node and micrometastatic-
involved subgroups, and selective lymphadenectomy and
minimally invasive approaches may be evaluated in these
situations. This demands prospective evaluation, but it may
be noteworthy that all involved nodes in the solitary
involved node cohort were close to the primary site and
may possibly have been identified as sentinel nodes.
In conclusion, this study shows that in a large cohort of
patients, lymph node status and the number of lymph nodes
positive at the time of surgical resection is directly linked to
survival. Extensive nodal involvement is confirmed as
carrying a dismal prognosis, but greater optimism is
justified where a solitary involved lymph gland defines
the pN stage after an adequate lymphadenectomy.
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